The MyCARdiac score integrating echocardiographic parameters, CAC score, and NT-proBNP identified high-risk RRMM patients treated with Cilta-cel with significantly reduced progression-free survival (p=0.008) and overall survival (p=0.037) compared to non-high-risk patients.
Observational (n=72)
No
Estimación del efecto: High LVPWd HR 1.59 (95% CI 1.15–2.19) for PFS; High LVM-Index HR 1.04 (95% CI 1.01–1.07) for PFS; Higher CAC score HR 1.35 (95% CI 1.05–1.72) for PFS; Elevated NT-proBNP HR 1.08 (95% CI 1.02–1.14) for PFS; Low LVEF trend HR 0.90 (95% CI 0.81–1.00) p=0.058 (95% CI See effect_size)
valor p: p=All adjusted p ≤ 0.05 except LVEF p=0.058 (trend)
Online First
Wiemers et al. (Tue,) conducted a observational in Patients with relapsed and refractory multiple myeloma (RRMM) undergoing ciltacabtagene autoleucel (Cilta-cel) CAR T-cell therapy (n=72). Ciltacabtagene autoleucel (Cilta-cel) CAR T-cell therapy vs. none (cohort observational) was evaluated on Progression-free survival (PFS) post-Cilta-cel infusion (High LVPWd HR 1.59 (95% CI 1.15–2.19) for PFS; High LVM-Index HR 1.04 (95% CI 1.01–1.07) for PFS; Higher CAC score HR 1.35 (95% CI 1.05–1.72) for PFS; Elevated NT-proBNP HR 1.08 (95% CI 1.02–1.14) for PFS; Low LVEF trend HR 0.90 (95% CI 0.81–1.00) p=0.058, 95% CI See effect_size, p=All adjusted p ≤ 0.05 except LVEF p=0.058 (trend)). The MyCARdiac score integrating echocardiographic parameters, CAC score, and NT-proBNP identified high-risk RRMM patients treated with Cilta-cel with significantly reduced progression-free survival (p=0.008) and overall survival (p=0.037) compared to non-high-risk patients.